If peptides worked, clinical practice guidelines would have included them

The strongest form of this objection deserves to be addressed before the rebuttal. Clinical practice guidelines — USPSTF, ACC/AHA, NICE, GOLD, GINA, IDSA, ASCO, ASH, the Endocrine Society series — are how the standard of care is operationalized. A guideline statement is the output of a multidisciplinary panel that has reviewed the trial body, weighted methodological quality, and concluded that an intervention belongs in routine practice at a defined strength of recommendation. Absence from a major guideline is information: usually it means the evidence base is too thin, the panel reviewed and found the evidence inadequate, or the intervention was actively rejected on safety or efficacy grounds. The serious response cannot wave the guideline framework away.

The honest move is disambiguation. "Not in the guidelines" collapses four very different situations. The first is active rejection — a panel has reviewed the molecule and recommended against it, or a regulator has voted down a marketing application. The second is not yet considered — the indication-specific Phase II/III trial body the panel would review does not yet exist. The third is included for the approved indication, not the off-label use — the molecule is in the guidelines for what it was approved to treat, while the off-label use being asked about is a separate question. The fourth is jurisdiction-specific — the molecule appears in non-US guidelines (the Russian Federation pharmacopeia, the EMA, the Chinese NMPA) but not in the US specialty-society documents the objection implicitly references. The four produce different epistemic positions; conflating them is what gives the bare objection its persuasive force.

Where the critique correctly identifies a negative signal — active rejection — the corpus does not look away. Salmon calcitonin nasal spray is the cleanest case: the /dossiers/osteoporosis-and-peptides treatment walks the 2013 joint FDA advisory committee 12-to-9 vote against continued marketing on the basis of pooled-trial cancer signal and modest fracture-reduction evidence. The SS-31 / elamipretide story is the second clean case: the MMPOWER-3 pivotal Phase III in primary mitochondrial myopathy did not meet either prespecified primary endpoint, and the molecule subsequently obtained FDA approval for Barth syndrome only. The /dossiers/failed-peptide-trials-archive catalogs the broader pattern — AOD-9604, elamipretide's ReCLAIM-2 and MMPOWER-3, liraglutide's ELAD, semaglutide's EVOKE / EVOKE+, anamorelin's ROMANA pair — each producing a primary-endpoint miss that the regulatory and guideline framework correctly weighted as negative information. When the critique points at this category, it is correctly read as informative.

The rebuttal becomes load-bearing when the critique extends from active rejection to not yet considered. The interval between a positive Phase III readout and major-guideline inclusion is a structural feature of evidence-to-practice translation, with the conventional estimate sitting in a 3-to-7-year window for a novel mechanism. Panels convene on multi-year update cycles; a single pivotal trial typically needs replication or open-label-extension data before a strong recommendation; cost-effectiveness appraisal in publicly-funded systems adds a second layer; editorial committees apply methodological filters (GRADE, AGREE-II) that score evidence depth against alternative comparators. The interim period — strong RCT evidence, regulatory approval, no formal guideline statement yet — is the typical state in the first years after approval, not evidence of negative judgment.

The contemporary GLP-1 / GIP-GLP-1 class illustrates the lag in motion. Tirzepatide received FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity on December 20, 2024, on the basis of SURMOUNT-OSA (Malhotra et al., N Engl J Med 2024, 391:1193-1205) — a 469-patient two-trial Phase III program that produced 25-29 events/hour AHI reduction and 42-50% disease-remission at week 52. The American Academy of Sleep Medicine has issued practitioner guidance on prescribing tirzepatide for OSA, and the formal AASM clinical practice guideline update was in process as of early 2026; the intervening period is the structural lag, not a panel verdict. The 2023 ESC focused update of the heart-failure guidelines is the other side of the same pattern — recommendations for GLP-1 receptor agonism in obesity-associated HFpEF draw on STEP-HFpEF (Kosiborod et al., N Engl J Med 2023, 389:1069-1084) and the SUMMIT readout published in late 2024 (Packer et al., N Engl J Med 2025), in which tirzepatide produced a hazard ratio of 0.62 for the composite of cardiovascular death or worsening HF events. The SELECT trial for semaglutide reduced the cardiovascular composite primary by 20% in 17,604 patients with established CVD and obesity without diabetes, moving into ACC/AHA secondary-prevention conversation within the same window. Lanreotide depot for gastroenteropancreatic neuroendocrine tumors moved into NCCN and ENETS guidelines on the basis of Caplin et al., N Engl J Med 2014, 371:224-233 (CLARINET) within roughly two years of the pivotal readout. When a peptide produces a clear Phase III signal in an indication a panel is positioned to review, the guideline catches up. The /dossiers/sleep-apnea-and-peptides treatment walks the SURMOUNT-OSA case in detail.

The harder case — and the one this objection is most often deployed against — is the set of research-grade molecules where the indication-RCT base does not yet exist. The /critic/no-human-rcts treatment is the canonical sibling response. BPC-157, TB-500, KPV, Selank, Semax, Dihexa, MOTS-c, DSIP, Epitalon — the rodent-and-small-cohort end of the corpus — will not be in major Western guidelines until Phase II and III RCTs in defined indications are completed and published. This is not because panels have considered and rejected them; it is because the trial body that would feed a panel review does not yet exist. Some have parallel non-US guideline traction — Selank carries a Russian Federation pharmacopeia entry for generalized anxiety disorder, Cerebrolysin appears in Eastern European and Asian stroke guidelines — walked in /critic/russian-peptides-decades-safety-record-myth and /critic/selank-russian-evidence. The /critic/small-studies-placebo treatment addresses the related question of how to read underpowered cohorts that lack the trial design a panel would require.

A separate category inside the objection is worth surfacing. Several peptides on this site appear in major US guidelines for their approved indications and are absent for the off-label use case that drives most contemporary biohacker interest. Semaglutide and tirzepatide sit in the ADA Standards of Care, the AACE algorithm for type 2 diabetes, the obesity-medicine literature, the 2023 ESC focused update for HFpEF, and the ACC/AHA secondary-prevention context — while the Alzheimer's indication tested in ELAD and EVOKE / EVOKE+ failed prespecified primaries and is correctly absent from dementia guidelines. Tesamorelin appears in HIV-care guidelines for lipodystrophy; off-label body-composition use does not. Octreotide and lanreotide — covered on the somatostatin analog class page — sit in NCCN and ENETS for GEP-NETs; their off-label use does not. The objection in this form is true about off-label use without doing work against the approved indication.

The honest synthesis: guideline inclusion is necessary but not sufficient evidence of clinical utility. Necessary, in that a molecule with strong RCT evidence in a defined indication will enter the relevant guideline if the trial body holds up to scrutiny — and absence persisting many years past approval is itself a negative signal. Not sufficient, in that the absence of a statement does not by itself establish negative outcome, particularly for molecules in the not yet considered category or for off-label use of molecules already included on their approved indication. The bare claim that "if peptides worked, the guidelines would already include them" works only if the corpus is treated as monolithic, and the corpus on this site is explicitly not. The objection is most informative when it is most specific; it does its least useful work when deployed as a class-level dismissal of the field.